Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.20.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
CONSOLIDATED STATEMENTS OF OPERATIONS    
Revenues
Operating expenses:    
General and administrative 787,293 298,951
Total operating expenses 787,293 298,951
Loss from operations (787,293) (298,951)
Other income (expense):    
Gain on fair value adjustment - derivatives 4,150
Interest expense (457,505) (263,092)
Amortization of interest - beneficial conversion feature (5,589)  
Amortization - debt discount (5,920) (80)
Total other income (expense) (464,864) (263,172)
Loss before provision for income taxes (1,252,157) (562,123)
Provision for income tax
Net loss (1,252,157) (562,123)
Net loss attributable to noncontrolling interest 3,125 3,158
Net loss attributable to TranBiotec, Inc. $ (1,249,032) $ (558,965)
Net loss per share    
(Basic and fully diluted) $ (0.007) $ (0.005)
Weighted average number of common shares outstanding 168,998,130 114,542,302